Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status JLT Raquel Albero-González, Silvia Hernández-Llodrà, Nuria Juanpere, Marta ... Virchows Archiv, 2019 | 24 | 2019 |
ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression S Hernández-Llodrà, N Juanpere, S de Muga, M Lorenzo, J Gil, ... Oncotarget 8 (43), 74106, 2017 | 20 | 2017 |
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG ‐rearranged prostate cancer JLT Silvia Hernández‐Llodrà, Laura Segalés, Ainara Safont, Nuria Juanpere ... The Prostate 79 (10), 1156-1165, 2019 | 17 | 2019 |
SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence S Hernández‐Llodrà, L Segales, N Juanpere, T Marta Lorenzo, M Salido, ... The Prostate 81 (16), 1267-1277, 2021 | 9 | 2021 |
Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome SHL Laura Segalés, Nuria Juanpere, Marta Lorenzo, Raquel Albero-González ... Virchows Archiv, 2019 | 9 | 2019 |
Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer L Segalés, N Juanpere, N Gallarín, M Lorenzo, D López, J Perera-Bel, ... Virchows Archiv, 1-10, 2023 | 1 | 2023 |
ERG expression in HGPIN is a marker of coexisting adenocarcinoma-a pilot study in totally embedded cystoprostatectomy specimens N Juanpere Rodero, A Martinez, M Lorenzo, L Segales, S Hernandez, ... VIRCHOWS ARCHIV 477, S161-S161, 2020 | | 2020 |
SPOP and CHD1 Alterations in Prostate Cancer. Relationship with PTEN Loss and Grade Group Classification S Hernández-Llodrà, L Segalés, N Juanpere, M Lorenzo, L Fumadó, ... 109th United States and Canada Academy of Pathologists annual Meeting. Los …, 2020 | | 2020 |
ETS2 Loss of Expression in Prostate Cancer L Segalés, J Lloreta, N Juanpere, M Lorenzo, L Fumadó, L Cecchinni, ... 109th United States and Canada Academy of Pathologists annual Meeting. Los …, 2020 | | 2020 |
SPOP and FOXA1 alterations in prostate cancer. Relationship with ERG overexpression and grade group classification. LCJL Silvia Hernández-Llodrà, Laura Segalés, Ainara Safont, Nuria Juanpere ... 16th ASEICA International Congress. Valencia, 5-8 of November, 2018., 2018 | | 2018 |
Strong ETV1 expression is associated with PSA recurrence in prostate cancer, in spite of low ETS gene overexpression in GG5 tumors. SHL Laura Segalés, Nuria Juanpere, Marta Lorenzo, Lluís Fumadó, Lluís ... 16th ASEICA International Congress. Valencia, 5-8 of November, 2018., 2018 | | 2018 |
SPOP mRNA downregulation is associated with the presence of the TMPRSS2-ERG fusion and PTEN loss on Prostate Cancer. BLJL Silvia Hernández-Llodrà, Laura Segalés, Nuria Juanpere, Marta Lorenzo ... 107th United States and Canada Academy of Pathologists annual Meeting …, 2018 | | 2018 |
ETS genes (ERG, ETV1, ETV4 and ETV5) overexpression and PTEN loss in Prostate Cancer. SHL Laura Segalés, Nuria Juanpere, Sílvia de Muga, Marta Lorenzo, Lluis ... 107th United States and Canada Academy of Pathologists annual Meeting …, 2018 | | 2018 |
Overexpression of ETS genes (ERG, ETV1, ETV4 and ETV5) in Prostate Cancer. SHL Laura Segalés, Nuria Juanpere, Sílvia de Muga, Marta Lorenzo, Lluis ... 1st DCEXS-UPF PhD Students' Symposium. Barcelona, 24 of November, 2017., 2017 | | 2017 |
FGFR3 mutations analysis in urine samples can be used as a marker of Bladder Cancer detection. JLSHL Francesc Alameda, Laura Segalés, Marta Lorenzo, Núria Juanpere ... 29th European Congress of Pathology. Amsterdam, 2 – 6 of September, 2017., 2017 | | 2017 |
Overexpression of ETS genes (ERG, ETV1, ETV4 and ETV5) in Prostate Cancer. LCJL Sílvia Hernández-Llodrà, Laura Segalés, Silvia de Muga, Nuria Juanpere ... 29th European Congress of Pathology. Amsterdam, 2 – 6 of September, 2017., 2017 | | 2017 |
High ETV1 levels are associated with shorter PSA-progression time in prostate cancer, but ETS overexpression is lower in GG5 tumors L Segalés, N Juanpere, M Lorenzo, L Fumadó, L Cecchini, J Lloreta-Trull, ... | | |